Reports

Ideas That Generate Results

1. Analyst View

2. Research Methodology

3. APIs - An Introduction

4. Industry Performance
     4.1 Current and Future Market Analysis to 2017
     4.2 Market Segments
            4.2.1 Branded and Generic APIs
            4.2.2 Synthetic and Biotech APIs
     4.3 Future Opportunity Assessment

5. Countries’ Comparative Analysis: API Manufacturing
     5.1 Labor Cost and Productivity
     5.2 Price Structure
     5.3 Investment Cost in Plant Set-up

6. Analysis by Therapeutic Segments
     6.1 Central Nervous System Disorders
     6.2 Cardiovascular Diseases
     6.3 Diabetes
     6.4 Respiratory Disorders
     6.5 Oncology

7. Key Geographical Markets
     7.1 China
            7.1.1 Current and Future Market Analysis to 2017
            7.1.2 Regional Segmentation
            7.1.3 Regulatory Environment
            7.1.4 Future Opportunity Assessment
     7.2 India
            7.2.1 Current and Future Market Analysis to 2017
            7.2.2 Regional Segmentation
            7.2.3 Regulatory Environment
            7.2.4 Future Opportunity Assessment
     7.3 Italy
            7.3.1 Current and Future Market Analysis to 2017
            7.3.2 Regulatory Environment
            7.3.3 Future Opportunity Assessment
     7.4 Taiwan

8. High-Potency APIs: An Emerging Opportunity

9. Regulatory Environment

10. Competitive Landscape
     10.1 Dr Reddy’s Laboratories
     10.2 Cipla
     10.3 Ranbaxy Laboratories
     10.4 Zhejiang Hisun Pharmaceutical Co. Ltd.
     10.5 Fabbrica Italiana Sintetici
     10.6 Cambrex Corporation
     10.7 Pfizer CentreSource
     10.8 Teva Active Pharmaceutical Ingredients
     10.9 Lonza
     10.10 Daiichi Fine Chemicals
     10.11 Boehringer Ingelheim GmbH
     10.12 BASF SE
     10.13 Royal DSM
     10.14 Divis Laboratories Limited
     10.15 Aurobindo Pharma Limited